Nuvation Bio (NUVB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
Annual Meeting scheduled for May 21, 2026, via live webcast, with record date of March 25, 2026.
Stockholders will vote on director elections, ratification of KPMG LLP as auditor, and an advisory say-on-pay vote.
Voting instructions provided for online, phone, and mail participation; quorum requirements detailed.
Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Three proposals: election of three directors, ratification of KPMG LLP as auditor for 2026, and advisory approval of executive compensation.
Class A and Class B stockholders vote together for two directors; Class B stockholders vote separately for one director.
Stockholder proposals for the 2027 meeting must be submitted by December 11, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
Board consists of seven members, divided into three classes with staggered three-year terms.
Majority of directors are independent per NYSE standards; Dr. Hung serves as Board Chair, Mr. Bazemore as Lead Independent Director.
Board committees: audit, compensation, and nominating/corporate governance, each with defined charters and responsibilities.
Board and committees met regularly in 2025, with all directors attending at least 75% of meetings.
Latest events from Nuvation Bio
- IBTROZI leads in ROS1 lung cancer with rapid uptake, superior efficacy, and expanding indications.NUVB
The Citizens Life Sciences Conference 202611 Mar 2026 - Strong growth, expanding first-line use, and robust pipeline drive confidence for 2024.NUVB
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - IBTROZI's clinical success and global deals drive growth, with safusidenib advancing in pivotal trials.NUVB
Corporate presentation3 Mar 2026 - Rapid IBTROZI uptake, Eisai partnership, and safusidenib trials drive long-term growth.NUVB
Q4 20253 Mar 2026 - FDA approval and rapid IBTROZI launch drove strong Q2 revenue and robust cash reserves.NUVB
Q2 20253 Feb 2026 - IBTROZI's launch success and robust pipeline are backed by strong data and financial strength.NUVB
H.C. Wainwright 27th Annual Global Investment Conference3 Feb 2026 - Late-stage oncology assets advance toward launch as strong data and cash position drive growth.NUVB
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Taletrectinib leads with superior efficacy as NDA filing and US launch approach next year.NUVB
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Ibtrozi leads ROS1 NSCLC with elite efficacy; safusidenib excels in glioma trials.NUVB
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026